Pipeline VP-103

Verrica intends to develop VP-103, a second cantharidin-based drug-device product candidate for the treatment of plantar warts, a skin infection on the bottom of the foot caused by the human papilloma virus (HPV). Plantar warts account for an estimated one-third of the approximately 4.1 million annual patient visits for all warts. To date, they have been difficult to treat, as they are refractory and available treatments often lead to both pain and scarring.

  • PRE-IND
  • Phase 2
  • Phase 3
  • Next Expected
    Milestone
VP-103
PLANTAR
WARTS
0%
Initiate
Phase 2 trial*
*Timing for initiating new clinical trials to be determined.
We retain exclusive royalty-free rights to our product candidates across all indications globally